Collectively, these findings indicate that NAT10 expression is significantly associated with the development of drug resistance and adverse clinical outcomes, such as advanced tumor stage and poor prognosis, in NSCLC. This evidence concerns the gene NAT10 and non-small cell lung carcinoma.